The key issue for the FTC is whether the deal kills competition between Concert's treatment and Vertex's Kalydeco.
Clariant and Huntsman announce $20 billion 'Merger of Equals.'
Wake Up Wall Street: Political Upheaval Surrounding President Trump Shows No Sign of Abating
Lion Biotechnologies, XBiotech and Halozyme Therapeutics were among the biotech movers in premarket trading on Friday.
Sage Therapeutics, Incyte and Shire were among the biotech movers in premarket trading on Thursday.
The new enasidenib data -- improved tumor response rate but shorter duration -- were made public on Wednesday night in a research abstract.
Insiders at Kite Pharma, Cliffs Natural Resources and three other companies have been buying up shares of their own stock recently.
The company's new CEO tells analysts it continues to believe the novel painkiller Nucynta can be a blockbuster.